News & Updates
Filter by Specialty:
Atezolizumab-chemo confers durable survival benefit in ES-SCLC
27 Sep 2023
byAudrey Abella
In the merged analysis of the IMpower133 trial and IMbrella A open-label extension study, the combination of the PD-L1 inhibitor atezolizumab and a chemotherapy regimen comprising carboplatin and etoposide (CP/ET) demonstrated potential for survival benefit of up to 5 years in patients with extensive stage-small-cell lung cancer (ES-SCLC).
Atezolizumab-chemo confers durable survival benefit in ES-SCLC
27 Sep 2023Calcium-channel blocker use ups glaucoma prevalence
26 Sep 2023
byStephen Padilla
Use of calcium-channel blockers (CCBs) appears to increase the risk of developing glaucoma, suggests a study. In addition, use of systemic beta blockers is associated with lower intraocular pressure (IOP).
Calcium-channel blocker use ups glaucoma prevalence
26 Sep 2023Passive smoking: Does it influence risk of childhood atopic eczema, food allergy?
26 Sep 2023
byAudrey Abella
A systematic review and meta-analysis from Singapore demonstrates that parental smoking is not a strong risk factor for offspring eczema, food allergy, and food sensitization development.